Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Major Policy Turnaround, Chinese Premier's Office Lifts Restrictions On Foreign Investment In Hospitals

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In a major new policy change as part of sweeping health system reforms slated to be introduced in stages through the year 2020, the Chinese premier's office, or State Council, is lowering decades-old barriers on foreign investment in and control of hospitals across the country

You may also be interested in...



President Lee Nominates Competition-friendly Bureaucrat As New Health Minister

SEOUL - South Korea President Lee Myung-bak nominated a new minister of Health and Welfare in a partial cabinet shuffle Aug. 30, and his nominee is viewed as a market-oriented bureaucrat who could introduce foreign-friendly policies for Korea's healthcare market

President Lee Nominates Competition-friendly Bureaucrat As New Health Minister

SEOUL - South Korea President Lee Myung-bak nominated a new minister of Health and Welfare in a partial cabinet shuffle Aug. 30, and his nominee is viewed as a market-oriented bureaucrat who could introduce foreign-friendly policies for Korea's healthcare market

A Closer Look: Investor Returns For Hospitals In Emerging Markets

SINGAPORE - As emerging markets grow, governments are pumping funds into upgrading hospitals and many offer incentives for foreign investment

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel